Remove Dermatitis Remove Eczema Remove Office
article thumbnail

Navigating Eczema: How a Dermatologist Can Help Manage Atopic Dermatitis

US Dermatologt Partners

Atopic Dermatitis, more commonly known as eczema, is a common skin condition impacting one in 10 Americans. Dermatology Partners affiliate office Medical Dermatology Specialists in Phoenix, Arizona , “Like other chronic skin conditions, eczema is best managed with the help of a dermatologist.

Eczema 36
article thumbnail

NEA Study Seeks to Refine Definition of Eczema Flares: Here’s What They Found

The Dermatology Digest

What is an eczema flare? Flare is commonly used in eczema care and clinical research, but there’s been little agreement on what it means until now. Focus group participants were mostly female (69%), Asian or Asian American (35%), 18–35 years old (62%) and diagnosed with eczema in childhood (83%).

Eczema 36
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

One-on-One: TDD/JDNPPA Talks to Kristin Belleson, the National Eczema Association’s New President and CEO

The Dermatology Digest

Belleson, also an eczema patient, is based in Indiana and has served as the CEO of the American College of Sports Medicine and the chief operating officer of the American Osteopathic Association. have eczema. Having an opportunity to work directly with patients living with eczema is very impactful.

Eczema 36
article thumbnail

NEA Survey: Fully Half of AD Patients Never Asked About Mental Health

The Dermatology Digest

Eczema is known to take a toll on emotional wellbeing and quality of life, yet 42% of patients with atopic dermatitis (AD) and caregivers of children/teens with eczema have never spoken about mental health with primary eczema care providers, according to new survey results from The National Eczema Association (NEA) in Skin Health and Disease.

Eczema 36
article thumbnail

Dermavant Submits Supplemental sNDA to FDA for VTAMA Cream for AD in Adults and Children 2 Years of Age and Older  

The Dermatology Digest

and is the same strength and formulation studied in the ADORING Phase 3 development program and included in the sNDA submission for atopic dermatitis. Dermavant Sciences has submitted a Supplemental New Drug Application (sNDA) to the U.S. VTAMA cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S.

article thumbnail

Treg Hypothesis Validated in Inflammatory Skin Diseases: Rezpegaldesleukin Shows Promise in AD, PsO

The Dermatology Digest

Rezpegaldesleukin showed durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes in patients with atopic dermatitis (AD) and psoriasis (PsO), according to two Phase 1b studies in Nature Communications. Chief Research & Development Officer at Nektar.

article thumbnail

TDD AD Pipeline Watch:  Aldeyra’s ADX?629 Performs Well in Phase 2 Study 

The Dermatology Digest

Aldeyra Therapeutics’ investigational RASP modulator ADX-629 performed well in a Phase 2 clinical trial of patients with atopic dermatitis (AD), according to topline results. Brady, MD, PhD, President and Chief Executive Officer of Aldeyra. The primary endpoint of the clinical trial was safety and tolerability.